ZA982819B - Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. - Google Patents
Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.Info
- Publication number
- ZA982819B ZA982819B ZA9802819A ZA982819A ZA982819B ZA 982819 B ZA982819 B ZA 982819B ZA 9802819 A ZA9802819 A ZA 9802819A ZA 982819 A ZA982819 A ZA 982819A ZA 982819 B ZA982819 B ZA 982819B
- Authority
- ZA
- South Africa
- Prior art keywords
- estrogn
- prophylaxis
- selective
- treatment
- receptor modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4322397P | 1997-04-09 | 1997-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA982819B true ZA982819B (en) | 1999-10-04 |
Family
ID=21926126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9802819A ZA982819B (en) | 1997-04-09 | 1998-04-02 | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0975629A4 (en) |
| JP (1) | JP2001518900A (en) |
| KR (1) | KR20010006218A (en) |
| CN (1) | CN1259944A (en) |
| AU (1) | AU6966198A (en) |
| BR (1) | BR9808515A (en) |
| CA (1) | CA2286204A1 (en) |
| EA (1) | EA199900914A1 (en) |
| HU (1) | HUP0003589A3 (en) |
| ID (1) | ID24358A (en) |
| IL (1) | IL132277A0 (en) |
| NO (1) | NO994903L (en) |
| PL (1) | PL336205A1 (en) |
| TR (1) | TR199902701T2 (en) |
| WO (1) | WO1998045288A1 (en) |
| ZA (1) | ZA982819B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
| EP1392304A1 (en) * | 2001-05-10 | 2004-03-03 | Cedars Sinai Medical Center | Use of benzothiophenes to treat and prevent prostate cancer |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| WO2007135547A2 (en) * | 2006-05-22 | 2007-11-29 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
| JP5558358B2 (en) | 2007-10-16 | 2014-07-23 | レプロス セラピューティクス インコーポレイティド | TRANS-clomiphene for metabolic syndrome |
| CA2865234A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
| EP3360870A1 (en) | 2013-02-19 | 2018-08-15 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| AU2016352592B2 (en) | 2015-11-10 | 2023-04-27 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429922A (en) * | 1988-03-09 | 1995-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for distinguishing virulent and non-virulent toxoplasma infections |
| US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
| PE44597A1 (en) * | 1995-02-28 | 1997-10-13 | Lilly Co Eli | BENZOTIOFEN COMPOUNDS, INTERMEDIATE PRODUCTS, COMPOSITIONS AND PROCEDURES |
| US5731342A (en) * | 1996-02-22 | 1998-03-24 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
-
1998
- 1998-04-02 ZA ZA9802819A patent/ZA982819B/en unknown
- 1998-04-07 ID IDW991188A patent/ID24358A/en unknown
- 1998-04-07 HU HU0003589A patent/HUP0003589A3/en unknown
- 1998-04-07 KR KR1019997009298A patent/KR20010006218A/en not_active Application Discontinuation
- 1998-04-07 JP JP54316898A patent/JP2001518900A/en active Pending
- 1998-04-07 EA EA199900914A patent/EA199900914A1/en unknown
- 1998-04-07 BR BR9808515-8A patent/BR9808515A/en not_active Application Discontinuation
- 1998-04-07 AU AU69661/98A patent/AU6966198A/en not_active Abandoned
- 1998-04-07 CN CN98805956A patent/CN1259944A/en active Pending
- 1998-04-07 WO PCT/US1998/007274 patent/WO1998045288A1/en not_active Application Discontinuation
- 1998-04-07 IL IL13227798A patent/IL132277A0/en unknown
- 1998-04-07 TR TR1999/02701T patent/TR199902701T2/en unknown
- 1998-04-07 CA CA002286204A patent/CA2286204A1/en not_active Abandoned
- 1998-04-07 EP EP98915488A patent/EP0975629A4/en not_active Withdrawn
- 1998-04-07 PL PL98336205A patent/PL336205A1/en unknown
-
1999
- 1999-10-08 NO NO994903A patent/NO994903L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL336205A1 (en) | 2000-06-05 |
| NO994903D0 (en) | 1999-10-08 |
| NO994903L (en) | 1999-12-09 |
| HUP0003589A2 (en) | 2002-01-28 |
| EP0975629A1 (en) | 2000-02-02 |
| ID24358A (en) | 2000-07-13 |
| WO1998045288A1 (en) | 1998-10-15 |
| IL132277A0 (en) | 2001-03-19 |
| CA2286204A1 (en) | 1998-10-15 |
| HUP0003589A3 (en) | 2002-02-28 |
| EA199900914A1 (en) | 2000-04-24 |
| EP0975629A4 (en) | 2001-03-21 |
| JP2001518900A (en) | 2001-10-16 |
| KR20010006218A (en) | 2001-01-26 |
| TR199902701T2 (en) | 2000-02-21 |
| CN1259944A (en) | 2000-07-12 |
| BR9808515A (en) | 2001-06-19 |
| AU6966198A (en) | 1998-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI0968208T1 (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
| AU6393896A (en) | Method for treating benign prostatic hyperplasia with thermal therapy | |
| AU3011299A (en) | Combination therapy for the treatment of benign prostatic hyperplasia | |
| DK0925069T3 (en) | Use of Cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer | |
| AU1316000A (en) | Compositions and methods for treating benign prostatic hyperplasia using tocotrienols | |
| ZA982819B (en) | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. | |
| AU1657097A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
| EP0855910A4 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| ZA983968B (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia. | |
| HK1030776A1 (en) | Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia | |
| ZA962141B (en) | Treatment and prevention of prostatic cancer. | |
| AU9128998A (en) | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis | |
| AU6570998A (en) | Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis | |
| EP0748627A3 (en) | Melatonin agonists for use in the treatment of benign prostatic hyperplasia | |
| ZA991319B (en) | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
| EP1140906A4 (en) | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders | |
| GB9810895D0 (en) | Combination therapy for the treatment of benign prostatic hyperplasia | |
| GB9602903D0 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| SI0925069T1 (en) | Use of cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer | |
| AU2003204320A1 (en) | Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof | |
| ZA922810B (en) | New combination treatment for benign prostatic hyperplasia | |
| AUPO410796A0 (en) | Method of treating benign prostatic hyperplasia | |
| ZA988293B (en) | Compositions and methods for the treatment of tumor. |